Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
NextCure, Inc. has 8 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either NextCure, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Prev close 6.35 · gapped above the open, then crossed back over prior close. High/low 6.61 at 10:15 am ET, 6.21 at 1:45 pm ET.
NextCure, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In connection with the License Agreement, the Company also entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which the Company issued and sold to Simcere Zaiming, Inc. ("Simcere Zaiming"), a Delaware corporation and an affiliate of Zaiming, in a private placement, an aggregate of 338,636 shares (the "Shares") of the common stock of the Company, par value $0.001 per share, at a price of approximately $5.904 per Share for an aggregate purchase price of $2.0 million.”
FILING10-K0001104659-26-024137cik 0001661059
“LNCB74 is being advanced under a November 2022 Research Collaboration and Co-Development Agreement (the "LigaChem Agreement") with LigaChem Biosciences, Inc., formerly known as LegoChem Biosciences, Inc ("LigaChem").”
FILING10-K0001104659-26-024137cik 0001661059
“We obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaiming's clinical-stage ADC candidate, SIM0505, and related compounds (the "Zaiming Products"), and (2) a non-exclusive, worldwide (excluding the Zaiming Territory) license to use Zaiming's ADC platform technology to develop ADCs based on the Company's proprietary antibodies for an additional novel target (the "NextCure Products") ("the License agreement").”
FILING10-K0001104659-26-024137cik 0001661059
“For example, WuXi XDC, which is currently the only CDMO we use to conjugate our B7-H4 antibody and produce LNCB74 ADC drug product, is affiliated with WuXi AppTec.”
FILING10-K0001104659-26-024137cik 0001661059
“We are party to a license agreement with Yale University under which we acquired rights to intellectual property related to certain of our product candidates.”
FILING10-K0001104659-26-024137cik 0001661059
“Our product candidate SIM0505 is a novel ADC candidate developed by Zaiming, to which we acquired the global rights (excluding China, Hong Kong, Macau and Taiwan) to develop, manufacture, and commercialize under the License Agreement, dated June 13, 2025, between the Company and Zaiming.”
FILING10-K0001104659-26-024137cik 0001661059
“On December 19, 2025, the Company entered into an at the market offering agreement (the "Wainwright ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $14.5 million of its Common Stock, through the Agent.”
FILING10-K0001104659-26-024137cik 0001661059
“On August 4, 2023, the Company entered into a sales agreement (the "Leerink ATM Agreement") with Leerink Partners LLC (the "Agent"), pursuant to which the Company was entitled to sell, from time to time, up to an aggregate sales price of $75 million of its common stock through the Agent in negotiated transactions that are deemed to be an "at the market offering."”
FILING10-K0001104659-26-024137cik 0001661059
“LNCB74 is being advanced under a November 2022 Research Collaboration and Co-Development Agreement (the "LigaChem Agreement") with LigaChem Biosciences, Inc., formerly known as LegoChem Biosciences, Inc ("LigaChem").”
FILING10-K0001104659-26-024137cik 0001661059
Watchlist prices, news filtered to it, and its next report on your desk.
NXTC (NextCure, Inc.) has 8 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.